Cancer & SURVIVEiT News
Category Filter:
FDA approves capmatinib for metastatic non-small cell lung cancer
FDA approves capmatinib for metastatic non-small cell lung cancer On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult…
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet…
One-Of-A-Kind List of Lung Cancer Experts | The Top Lung Cancer Doctors
SURVIVEiT®’s interactive Cancer Navigation Tool was built by survivors and medical experts to help you practically and efficiently navigate cancer care. We took our collective experience and things we wish…
The Tools That Allow Me To Address My Cancer With Less Fear and More Hope
When asked how Step 1 (TESTiT) and STEP 2 (VERIFYiT) of our Cancer Navigation Tool played a major part in her journey, this is what Peggy has to say. ——————————Guest…
FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression On February 22, 2021, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line…
FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer
FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for…
A Cancer Patient’s Experience With Immunotherapy
After a cancer diagnosis, it’s important that you gather as much information as you can so you can truly advocate for yourself. This includes understanding your specific type of cancer…
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for…
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC On May 26, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb…